Cellebrite
CLBT
11.23
-0.15
-1.28%
Cellebrite
US · CLBT
#2562 by market cap
Listed 1970
11.23
-0.15
-1.28%
Live - 5344 symbols - heartbeat 40s ago
· 2026-10-08 06:56
Pre-market
11.00
-2.00%
After-hours
11.23
0.00%
- Market cap
- 2.82B
- P/E (TTM)i
- 48.80
- P/Bi
- 5.24
- EPSi
- 0.31
- Div yieldi
- 0.00%
- 52W posi
- 16%
Reader sentiment
Are you bullish or bearish on CLBT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.60, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +18.56% YoY
Margins
- Gross margin
- 84.20%
- Operating margin
- 13.98%
- Net margin
- 16.36%
Key ratios & quality
- Altman Z-Scorei
- 4.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 171.85M | 194.91M | 246.25M | 270.65M | 325.11M | 401.20M | 475.68M |
| Gross profit | 136.03M | 157.03M | 203.69M | 219.91M | 271.88M | 338.61M | 400.50M |
| Selling & admin expenses | 90.23M | 93.44M | 124.33M | 138.24M | 154.26M | 183.29M | 220.15M |
| Research & development | 46.57M | 54.38M | 65.54M | 80.62M | 84.39M | 98.42M | 113.88M |
| Operating profit | -1.52M | 9.22M | 13.82M | 1.04M | 33.24M | 56.91M | 66.48M |
| Pretax profit | 1.42M | 11.40M | 82.31M | 120.76M | -75.56M | -275.98M | 90.68M |
| Tax | 3.29M | 5.62M | 10.91M | -45.00K | 5.54M | 7.02M | 12.35M |
| Net profit | -1.88M | 5.78M | 71.40M | 120.81M | -81.10M | -283.01M | 78.33M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | -1 | 0 |
| Diluted EPS | -0.05 | -0.05 | 0.44 | 0.59 | -0.43 | -1.35 | 0.31 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 107.55M | 113.28M | 126.03M | 128.82M | 128.30M | 131.14M |
| Gross profit | 90.06M | 95.60M | 105.72M | 109.13M | 105.88M | 105.93M |
| Selling & admin expenses | 50.51M | 52.57M | 58.60M | 58.46M | 60.89M | 63.02M |
| Research & development | 27.28M | 28.61M | 28.12M | 29.87M | 35.87M | 35.96M |
| Operating profit | 12.27M | 14.42M | 18.99M | 20.81M | 9.12M | 6.95M |
| Pretax profit | 19.33M | 20.79M | 24.29M | 26.27M | 13.63M | 11.19M |
| Tax | 1.93M | 1.32M | 4.10M | 5.01M | 2.70M | 4.82M |
| Net profit | 17.40M | 19.48M | 20.19M | 21.26M | 10.94M | 6.37M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.07 | 0.08 | 0.08 | 0.08 | 0.04 | 0.02 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 261.88M | 324.27M | 273.21M | 295.93M | 422.08M | 567.59M | 575.85M |
| Cash & ST investments | 200.25M | 237.64M | 181.57M | 183.62M | 302.92M | 447.22M | 437.05M |
| Inventory | 3.96M | 4.75M | 6.51M | 10.18M | 9.94M | 8.94M | 7.60M |
| Total assets | 280.24M | 364.39M | 339.78M | 403.29M | 532.89M | 690.57M | 938.85M |
| Total current liabilities | 99.16M | 159.38M | 186.57M | 207.78M | 253.82M | 295.50M | 369.66M |
| Short-term debt | -- | -- | -- | 5.00M | 4.97M | 4.13M | 4.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 221,412,000.00 | 300,583,000.00 | 413,130,000.00 | 329,428,000.00 | 498,673,000.00 | 354,547,000.00 | 454,534,000.00 |
| Total equity | 58.83M | 63.80M | -73.35M | 73.87M | 34.21M | 336.02M | 484.32M |
| Retained earnings | 32.56M | 28.34M | 78.44M | 199.24M | 118.14M | -164.86M | -86.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 523.48M | 606.11M | 668.40M | 575.85M | 540.87M | 589.68M |
| Cash & ST investments | 409.49M | 472.18M | 525.71M | 437.05M | 429.07M | 442.53M |
| Inventory | 8.97M | 9.54M | 8.65M | 7.60M | 7.53M | 8.39M |
| Total assets | 709.89M | 787.43M | 834.32M | 938.85M | 952.29M | 994.31M |
| Total current liabilities | 287.80M | 309.97M | 316.92M | 369.66M | 350.21M | 364.21M |
| Short-term debt | 4.21M | 4.24M | 3.62M | 4.00M | 4.60M | 5.74M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 346,398,000.00 | 379,012,000.00 | 386,634,000.00 | 454,534,000.00 | 441,746,000.00 | 456,214,000.00 |
| Total equity | 363.49M | 408.41M | 447.69M | 484.32M | 510.54M | 538.10M |
| Retained earnings | -147.46M | -127.99M | -107.80M | -86.54M | -75.60M | -69.23M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 16.13M | 66.51M | 36.05M | 20.58M | 102.06M | 132.17M | 173.54M |
| Depreciation & amortization | 4.08M | 5.88M | 7.01M | 9.19M | 10.01M | 10.61M | 11.87M |
| Free cash flow | 9.92M | 60.33M | 27.94M | 11.49M | 94.14M | 121.56M | 160.32M |
| Dividends paid | -25.00M | -10.00M | -100.00M | -- | -- | -- | -- |
| Stock buybacks / issuance | -808.00K | -85.00K | -- | -- | -- | -- | -- |
| Ending cash balance | 81.68M | 133.85M | 145.97M | 87.65M | 189.52M | 191.66M | 124.46M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 20.88M | 32.58M | 33.27M | 86.81M | 19.89M | 17.59M |
| Depreciation & amortization | 2.63M | 2.59M | 2.70M | 3.94M | 7.01M | 8.92M |
| Free cash flow | 18.54M | 28.98M | 29.95M | 82.86M | 9.79M | 5.96M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 90.48M | 179.22M | 281.36M | 124.46M | 133.69M | 141.25M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -17.07 | -15.24 | -- | 44,830.50 | -150.08 | -152.88 | 18.97 |
| ROA %i | -3.58 | -2.90 | 20.00 | 31.25 | -17.33 | -46.26 | 9.55 |
| ROIC %i | -21.44 | -18.64 | -- | 736.42 | -127.70 | -150.26 | 13.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.90 | 5.85 | 33.49 | 44.67 | -23.20 | -68.78 | 19.17 |
| FCF / sales %i | 5.77 | 30.95 | 11.35 | 4.25 | 28.96 | 30.30 | 33.70 |
| Current ratioi | 2.64 | 2.03 | 1.46 | 1.42 | 1.66 | 1.92 | 1.56 |
| Quick ratioi | 2.47 | 1.91 | 1.33 | 1.26 | 1.50 | 1.79 | 1.47 |
| Debt / assetsi | -- | -- | 0.00 | 3.81 | 2.65 | 1.59 | 2.41 |
| LT debt / equityi | -- | -- | -- | 14.02 | 26.77 | 2.04 | 3.86 |
| Interest coveragei | 11.88 | -- | 538.94 | 811.47 | -534.91 | -9,515.69 | 174.38 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 16.35 | 18.59 | 17.67 | 20.68 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -13.45 |
| FCF CAGR (3Y) %i | -- | -- | -- | 5.01 | 15.99 | 63.25 | 140.73 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -115.35 | -82.10 | 20.46 | 18.97 | 16.33 | 12.31 |
| ROA %i | -31.35 | -22.50 | 10.43 | 9.55 | 8.59 | 6.54 |
| ROIC %i | -107.81 | -84.30 | 19.58 | 13.48 | 15.73 | 8.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -65.11 | -33.07 | -59.54 | 19.17 | 17.74 | 15.67 |
| FCF / sales %i | 31.53 | 34.12 | 30.51 | 33.70 | 30.53 | 25.00 |
| Current ratioi | 1.82 | 1.96 | 2.11 | 1.56 | 1.54 | 1.62 |
| Quick ratioi | 1.70 | 1.82 | 1.99 | 1.47 | 1.43 | 1.52 |
| Debt / assetsi | 1.49 | 2.84 | 2.57 | 2.41 | 2.39 | 2.34 |
| LT debt / equityi | 1.76 | 4.43 | 3.98 | 3.86 | 3.57 | 3.25 |
| Interest coveragei | -- | -1,641.28 | -- | 174.38 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 06:56:53 · For reference only, not investment advice and not tailored to your situation.